A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

NICO Raises $12.5 Million in Oversubscribed Investment Round

Strong investor support pushes medtech innovator closer to mission of revolutionizing brain surgery

NICO Corporation completed a $12.5 million capital raise in an oversubscribed round that will scale the business and leverage continued progress on the company’s recently completed adaptive clinical trial for intracerebral hemorrhage (ICH) and new partnership in functional precision oncology for patients with deadly treatment-resistant GBM.

NICO’s target markets within neurosurgery are experiencing a major shift toward minimally invasive surgery (MIS) approaches, making them attractive markets based on size, patient need and opportunity. The company reported 25 percent revenue growth in 2021 and is on pace for similar growth this year.

With medical innovations being delivered at a rapid pace, the life science sector has proven to be a durable investment space – even amid the current economic climate. NICO’s investment round was led by RC Capital, with additional participation from existing NICO investors.

“NICO represents everything we look for in a medtech business – a large market opportunity, growing revenue, demonstrated clinical outcomes, patent-protected technology, and compelling hospital economics – all led by a serially successful executive team,” said J. Carter McNabb, managing partner at RC Capital. “The brain is really the final frontier for minimally invasive surgery in medtech, and NICO’s platform technology is the catalyst for that change.”

NICO has led the MIS neurosurgical field for over a decade with its unique set of technologies that do not require traditional methods of cutting through the brain to access abnormalities deep below the surface, but instead use the natural folds of the brain to reach abnormalities. Other technologies in its product family allow for safe removal of abnormalities or hemorrhages in a modern surgical suite, as well as biological preservation of tumor tissue for molecular profiling – enabling improved accuracy for today’s precision medicine treatments.

NICO is an Indianapolis-based medical device innovator creating a new reality in neurosurgery through its MIS technologies. The company has a strong shareholder base that has invested more than $62 million since its inception in 2007.

“Adoption rates have continued to grow, which has led to MIS being taught to neurosurgery residents. That’s how I know we have staying power,” said Jim Pearson, president and CEO of NICO. “It’s not a question of whether we will be successful. We are successful, and we’re in the middle of revolutionary changes happening in neurosurgery.”

NICO technologies have been featured in more than 180 peer-reviewed published papers with over 550 unique authors from major academic centers. For more information, visit NICOneuro.com, and follow the latest news on LinkedIn and Twitter.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy